Updates from The Motley Fool

Latest updates on Gilead Sciences from Fool.com.

Stock Performance

GILD vs. S&P 500 | 2 Year Performance
GILD 1-Day Stock Chart
GILD 5-Day Stock Chart
GILD 1-Month Stock Chart
GILD 3-Month Stock Chart
GILD 6-Month Stock Chart
GILD 1-Year Stock Chart
GILD 2-Year Stock Chart
GILD 5-Year Stock Chart
View Interactive GILD Charts
Sponsored by

Key Data Points

Primary metrics and data points about Gilead Sciences.
Current Price: $88.21
Prev Close: $97.00
Open: $91.19
Bid: $88.22
Ask: $88.30
Day's Range: $87.80 - $92.53
52wk Range: $81.89 - $123.37
Volume: 33,589,641
Avg Vol 10,484,416
Market Cap: $127.13B
P/E (ttm): 8.14
EPS (ttm): $11.91
Div & Yield: $1.72 (1.9%)

Company Rating

What our community thinks about Gilead Sciences.
CAPS Rating 5 out of 5
3549 Outperform
85 Underperform
CAPS All Stars
734 Outperform
13 Underperform

How do you think Gilead Sciences will perform against the market?

You pick for Gilead Sciences is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS

CEO Rating

The single most important factor in a company's success is the team that's leading the company.

John C. Martin, CEO

81% Approve

Based on 170 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Gilead Sciences.

Gilead Sciences created and sells the world’s top-selling HIV medications, Truvada and Atripla, and commands about 75% of the U.S. treatment market and more than 50% worldwide.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers